Short-term benefits of tamoxifen in Dupuytren patients with a predisposition to fibrosis .
This report has been verified
by one or more authors of the
original publication.
High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial
J Bone Joint Surg Am. 2014 Apr 16;96(8):655-6230 patients suffering from Dupuytren disease, with a predisposition toward fibrosis, were randomized to evaluate the efficacy of tamoxifen against a placebo, following subtotal fasciectomy. Patients were regularly assessed over 2 years to evaluate improvements of total passive extension deficit, and satisfaction as determined by the visual analogue scale (VAS).The evidence presented in this trial indicated that tamoxifen resulted in superior short-term outcomes of total passive extension deficit, and satisfaction, but beneficial effect disappeared within two years after surgery, with worsening of the contractures after the medication was discontinued at 2 years.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
